{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.2","upperLimit":"99.3","value":"89.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"Percent of B-LLy patients who had adequate/usable samples of samples collected will be reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction: same trt as B-ALL; Consolidation (4 wks): vincristine sulfate day 1; mercaptopurine days 1-28; IT methotrexate (MTX) days 1/8/15; leucovorin calcium days 3-4,10-11,17-18 Interim maintenance I (8 wks): vincristine sulfate and MTX 2-15 min days 1/11/21/31/41; IT MTX day 31; leucovorin calcium days 33-34 Delayed-intensification (8 wks): dexamethasone days 1-7 and 15-21; vincristine sulfate and doxorubicin hydrochloride on days 1/8/15; pegaspargase 1-2 hrs day 4; cyclophosphamide day 29; thioguanine days 29-42; cytarabine 29-32, 33-39; IT MTX days 1/29; and leucovorin calcium days 3-4, 31-32 Interim maintenance II (8 wks): vincristine sulfate and MTX days 1/11/21/31/41; IT MTX days 1/31; and leucovorin calcium days 3-4, 33/34 Maintenance: vincristine sulfate day 1; dexamethasone days 1-5; MTX weekly days 8-78; mercaptopurine days 1-84; and IT MTX day 1. Courses repeat every 4 wks for 2 yrs (from the start of IMI therapy).","id":"OG000","title":"B-LLy"}],"paramType":"NUMBER","populationDescription":"patients who had samples collected near diagnosis","reportingStatus":"POSTED","timeFrame":"Up to 1 month","title":"Sample Collection of Central Path Review Slides in B-LLy Patients","type":"PRIMARY","unitOfMeasure":"percentage of patients"}